HRP20010013A2 - Novel poly (adp-ribose)polymerase gene - Google Patents

Info

Publication number

HRP20010013A2

HRP20010013A2 HR20010013A HRP20010013A HRP20010013A2 HR P20010013 A2 HRP20010013 A2 HR P20010013A2 HR 20010013 A HR20010013 A HR 20010013A HR P20010013 A HRP20010013 A HR P20010013A HR P20010013 A2 HRP20010013 A2 HR P20010013A2

Authority

HR

Croatia

Prior art keywords

parp

adp

poly

seq

sequence

Prior art date

1998-06-05

Links

• Espacenet
• Global Dossier
• Discuss

• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title claims description 4
• 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims description 176
• 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims description 175
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 167
• -1 poly(ADP-ribose) Polymers 0.000 claims description 128
• 108090000623 proteins and genes Proteins 0.000 claims description 84
• 102000004169 proteins and genes Human genes 0.000 claims description 63
• 230000027455 binding Effects 0.000 claims description 57
• 238000000034 method Methods 0.000 claims description 49
• 150000007523 nucleic acids Chemical class 0.000 claims description 48
• 108020004414 DNA Proteins 0.000 claims description 42
• 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims description 42
• 241000282414 Homo sapiens Species 0.000 claims description 38
• 150000001413 amino acids Chemical class 0.000 claims description 38
• 230000014509 gene expression Effects 0.000 claims description 38
• 102000039446 nucleic acids Human genes 0.000 claims description 38
• 108020004707 nucleic acids Proteins 0.000 claims description 38
• 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 claims description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
• 239000002773 nucleotide Substances 0.000 claims description 30
• 125000003729 nucleotide group Chemical group 0.000 claims description 30
• BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 27
• 108010033040 Histones Proteins 0.000 claims description 22
• 239000012661 PARP inhibitor Substances 0.000 claims description 20
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 20
• 238000006243 chemical reaction Methods 0.000 claims description 18
• 239000013598 vector Substances 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 17
• 238000011534 incubation Methods 0.000 claims description 17
• 239000012491 analyte Substances 0.000 claims description 16
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
• 230000001105 regulatory effect Effects 0.000 claims description 16
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
• 102000045365 human PARP2 Human genes 0.000 claims description 15
• 102000045516 human PARP3 Human genes 0.000 claims description 14
• 230000001575 pathological effect Effects 0.000 claims description 14
• 201000010099 disease Diseases 0.000 claims description 13
• 239000012636 effector Substances 0.000 claims description 13
• 230000036961 partial effect Effects 0.000 claims description 13
• 238000001514 detection method Methods 0.000 claims description 12
• 239000012634 fragment Substances 0.000 claims description 12
• 230000005731 poly ADP ribosylation Effects 0.000 claims description 12
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
• 230000009471 action Effects 0.000 claims description 11
• 238000003745 diagnosis Methods 0.000 claims description 11
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 230000001404 mediated effect Effects 0.000 claims description 11
• 238000002560 therapeutic procedure Methods 0.000 claims description 11
• 239000000758 substrate Substances 0.000 claims description 10
• 230000009261 transgenic effect Effects 0.000 claims description 10
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
• 230000015572 biosynthetic process Effects 0.000 claims description 9
• 229910052725 zinc Inorganic materials 0.000 claims description 9
• 239000011701 zinc Substances 0.000 claims description 9
• 230000003197 catalytic effect Effects 0.000 claims description 8
• 241000124008 Mammalia Species 0.000 claims description 7
• 239000012190 activator Substances 0.000 claims description 7
• GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 claims description 7
• 238000001415 gene therapy Methods 0.000 claims description 7
• 229920001184 polypeptide Polymers 0.000 claims description 7
• 239000012472 biological sample Substances 0.000 claims description 6
• 150000001875 compounds Chemical class 0.000 claims description 6
• 238000011161 development Methods 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 230000002068 genetic effect Effects 0.000 claims description 6
• 108020004635 Complementary DNA Proteins 0.000 claims description 5
• 230000003321 amplification Effects 0.000 claims description 5
• 238000000338 in vitro Methods 0.000 claims description 5
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
• 239000011541 reaction mixture Substances 0.000 claims description 5
• 238000012546 transfer Methods 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 102000053642 Catalytic RNA Human genes 0.000 claims description 4
• 108090000994 Catalytic RNA Proteins 0.000 claims description 4
• 230000007812 deficiency Effects 0.000 claims description 4
• 244000005700 microbiome Species 0.000 claims description 4
• 239000008177 pharmaceutical agent Substances 0.000 claims description 4
• 108091092562 ribozyme Proteins 0.000 claims description 4
• 108090001008 Avidin Proteins 0.000 claims description 2
• 239000003155 DNA primer Substances 0.000 claims description 2
• 102100039869 Histone H2B type F-S Human genes 0.000 claims description 2
• 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims description 2
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims description 2
• 108010090804 Streptavidin Proteins 0.000 claims description 2
• 230000007850 degeneration Effects 0.000 claims description 2
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
• 239000003550 marker Substances 0.000 claims description 2
• 230000002950 deficient Effects 0.000 claims 2
• 230000008827 biological function Effects 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 description 58
• 235000001014 amino acid Nutrition 0.000 description 35
• 229940024606 amino acid Drugs 0.000 description 35
• 210000001519 tissue Anatomy 0.000 description 32
• 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 27
• 210000004556 brain Anatomy 0.000 description 25
• 210000004027 cell Anatomy 0.000 description 25
• 239000003112 inhibitor Substances 0.000 description 25
• 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 24
• 210000002216 heart Anatomy 0.000 description 24
• 239000000243 solution Substances 0.000 description 23
• 208000014674 injury Diseases 0.000 description 22
• 241001465754 Metazoa Species 0.000 description 21
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 21
• 208000028867 ischemia Diseases 0.000 description 21
• 239000000126 substance Substances 0.000 description 21
• 208000035475 disorder Diseases 0.000 description 20
• 239000002299 complementary DNA Substances 0.000 description 18
• 238000005259 measurement Methods 0.000 description 18
• 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 16
• 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 16
• 230000006378 damage Effects 0.000 description 16
• 210000003734 kidney Anatomy 0.000 description 16
• 238000012360 testing method Methods 0.000 description 16
• 208000027418 Wounds and injury Diseases 0.000 description 15
• 239000000872 buffer Substances 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 238000011282 treatment Methods 0.000 description 15
• 102000006947 Histones Human genes 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 13
• 208000006011 Stroke Diseases 0.000 description 13
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 12
• 108091026813 Poly(ADPribose) Proteins 0.000 description 12
• 241000196324 Embryophyta Species 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 239000013543 active substance Substances 0.000 description 11
• 239000000203 mixture Substances 0.000 description 11
• 238000005406 washing Methods 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 208000015122 neurodegenerative disease Diseases 0.000 description 10
• 210000000056 organ Anatomy 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 238000001262 western blot Methods 0.000 description 10
• 201000011510 cancer Diseases 0.000 description 9
• 238000009826 distribution Methods 0.000 description 9
• 238000009396 hybridization Methods 0.000 description 9
• 210000004185 liver Anatomy 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 229930195712 glutamate Natural products 0.000 description 8
• 230000001537 neural effect Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 239000011535 reaction buffer Substances 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 210000002027 skeletal muscle Anatomy 0.000 description 8
• 230000008733 trauma Effects 0.000 description 8
• 206010040070 Septic Shock Diseases 0.000 description 7
• 108010004469 allophycocyanin Proteins 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 238000006911 enzymatic reaction Methods 0.000 description 7
• 102000049595 human PARP1 Human genes 0.000 description 7
• 239000002953 phosphate buffered saline Substances 0.000 description 7
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 238000000636 Northern blotting Methods 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000007912 intraperitoneal administration Methods 0.000 description 6
• 208000010125 myocardial infarction Diseases 0.000 description 6
• 230000010410 reperfusion Effects 0.000 description 6
• 230000036303 septic shock Effects 0.000 description 6
• 210000000278 spinal cord Anatomy 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
• PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 5
• 208000009304 Acute Kidney Injury Diseases 0.000 description 5
• 102000004420 Creatine Kinase Human genes 0.000 description 5
• 108010042126 Creatine kinase Proteins 0.000 description 5
• 102000018899 Glutamate Receptors Human genes 0.000 description 5
• 108010027915 Glutamate Receptors Proteins 0.000 description 5
• 101100462856 Mus musculus Parp3 gene Proteins 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 208000025966 Neurological disease Diseases 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 239000003257 excitatory amino acid Substances 0.000 description 5
• 230000002461 excitatory amino acid Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 210000003657 middle cerebral artery Anatomy 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 208000037816 tissue injury Diseases 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 230000004568 DNA-binding Effects 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• 208000023105 Huntington disease Diseases 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• 206010061216 Infarction Diseases 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• 208000033626 Renal failure acute Diseases 0.000 description 4
• 239000006180 TBST buffer Substances 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 206010015037 epilepsy Diseases 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• 230000007574 infarction Effects 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 208000033808 peripheral neuropathy Diseases 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000005783 single-strand break Effects 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 210000001541 thymus gland Anatomy 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• 239000011534 wash buffer Substances 0.000 description 4
• SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 230000005778 DNA damage Effects 0.000 description 3
• 231100000277 DNA damage Toxicity 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 108700003473 Drosophila Parp Proteins 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 239000000020 Nitrocellulose Substances 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 102000003992 Peroxidases Human genes 0.000 description 3
• 208000001647 Renal Insufficiency Diseases 0.000 description 3
• 206010040047 Sepsis Diseases 0.000 description 3
• 108020004682 Single-Stranded DNA Proteins 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 201000011040 acute kidney failure Diseases 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000008485 antagonism Effects 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 230000033590 base-excision repair Effects 0.000 description 3
• 230000006287 biotinylation Effects 0.000 description 3
• 238000007413 biotinylation Methods 0.000 description 3
• 244000309466 calf Species 0.000 description 3
• 230000002490 cerebral effect Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000004140 cleaning Methods 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 210000004351 coronary vessel Anatomy 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 230000005670 electromagnetic radiation Effects 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 230000003492 excitotoxic effect Effects 0.000 description 3
• 231100000063 excitotoxicity Toxicity 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 238000003119 immunoblot Methods 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
• 201000006370 kidney failure Diseases 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 229920001220 nitrocellulos Polymers 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 230000010412 perfusion Effects 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 208000027232 peripheral nervous system disease Diseases 0.000 description 3
• 108040007629 peroxidase activity proteins Proteins 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 229940076155 protein modulator Drugs 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000009759 skin aging Effects 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 230000002861 ventricular Effects 0.000 description 3
• LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 230000033616 DNA repair Effects 0.000 description 2
• 231100001074 DNA strand break Toxicity 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 206010012289 Dementia Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 102000016942 Elastin Human genes 0.000 description 2
• 108010014258 Elastin Proteins 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 239000007836 KH2PO4 Substances 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 206010029350 Neurotoxicity Diseases 0.000 description 2
• 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• 102000007999 Nuclear Proteins Human genes 0.000 description 2
• 108010089610 Nuclear Proteins Proteins 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 108010053210 Phycocyanin Proteins 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 206010044221 Toxic encephalopathy Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 210000001638 cerebellum Anatomy 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 238000009509 drug development Methods 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 229920002549 elastin Polymers 0.000 description 2
• JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 2
• 229960000305 enflurane Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 210000001353 entorhinal cortex Anatomy 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000003191 femoral vein Anatomy 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 210000005153 frontal cortex Anatomy 0.000 description 2
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000012263 liquid product Substances 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000001259 mesencephalon Anatomy 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
• 235000019796 monopotassium phosphate Nutrition 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 210000001577 neostriatum Anatomy 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 231100000228 neurotoxicity Toxicity 0.000 description 2
• 230000007135 neurotoxicity Effects 0.000 description 2
• 239000002547 new drug Substances 0.000 description 2
• 210000000956 olfactory bulb Anatomy 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000008024 pharmaceutical diluent Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 108060006184 phycobiliprotein Proteins 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
• 238000000164 protein isolation Methods 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 239000002534 radiation-sensitizing agent Substances 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000000637 radiosensitizating effect Effects 0.000 description 2
• 210000002254 renal artery Anatomy 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 208000032253 retinal ischemia Diseases 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000012146 running buffer Substances 0.000 description 2
• 239000012723 sample buffer Substances 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• IWGAAKJQEXBTNA-JPQZOSAESA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;(4r)-4-[[(2s) Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO.S1C([C@@H](N)C(C)CC)=NCC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 IWGAAKJQEXBTNA-JPQZOSAESA-N 0.000 description 1
• AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
• MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
• BRDIFBARJKLSSY-UHFFFAOYSA-N 2,3,4-triphenyl-2h-tetrazol-2-ium;chloride Chemical compound [Cl-].C1=[NH+]N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 BRDIFBARJKLSSY-UHFFFAOYSA-N 0.000 description 1
• PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
• MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
• RVOUDNBEIXGHJY-UHFFFAOYSA-N 5-(4-piperidin-1-ylbutoxy)-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1OCCCCN1CCCCC1 RVOUDNBEIXGHJY-UHFFFAOYSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 241001479434 Agfa Species 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 241000219194 Arabidopsis Species 0.000 description 1
• 108010037365 Arabidopsis Proteins Proteins 0.000 description 1
• 241000219195 Arabidopsis thaliana Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 101100407072 Bos taurus PARP1 gene Proteins 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 241000244202 Caenorhabditis Species 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 208000021479 Cardiovascular injury Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 241000252203 Clupea harengus Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 241001643084 Cyrtanthus elatus virus A Species 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102100027834 DNA repair protein XRCC1 Human genes 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 101100407074 Gallus gallus PARP1 gene Proteins 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000649341 Homo sapiens DNA repair protein XRCC1 Proteins 0.000 description 1
• 101001028283 Homo sapiens FERM, ARHGEF and pleckstrin domain-containing protein 2 Proteins 0.000 description 1
• 101000738966 Homo sapiens POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 208000027382 Mental deterioration Diseases 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 206010027439 Metal poisoning Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100462852 Mus musculus Parp2 gene Proteins 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 206010028400 Mutagenic effect Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 108700024605 Nebacetin Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 206010034759 Petit mal epilepsy Diseases 0.000 description 1
• 101710163504 Phaseolin Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 101710176890 Protein ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
• 208000008425 Protein deficiency Diseases 0.000 description 1
• 101710204718 Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038470 Renal infarct Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 229910003798 SPO2 Inorganic materials 0.000 description 1
• 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
• 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 239000004141 Sodium laurylsulphate Substances 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• 229910052771 Terbium Inorganic materials 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 206010062129 Tongue neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 210000003815 abdominal wall Anatomy 0.000 description 1
• 108091006088 activator proteins Proteins 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 101150102866 adc1 gene Proteins 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 230000008321 arterial blood flow Effects 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 229950004398 broxuridine Drugs 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000002729 catgut Substances 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000006726 chronic neurodegeneration Effects 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000000562 conjugate Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 230000005782 double-strand break Effects 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 238000005265 energy consumption Methods 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000010855 food raising agent Nutrition 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
• 206010019680 hepatic infarction Diseases 0.000 description 1
• 235000019514 herring Nutrition 0.000 description 1
• 229940094991 herring sperm dna Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000043476 human FARP2 Human genes 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 208000008127 lead poisoning Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011670 long-evans rat Methods 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• 230000007576 microinfarct Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 231100000243 mutagenic effect Toxicity 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 229940105631 nembutal Drugs 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000009689 neuronal regeneration Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 229960003966 nicotinamide Drugs 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000002907 paramagnetic material Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 239000000863 peptide conjugate Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000020861 perceptual disease Diseases 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 239000013615 primer Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 229910052761 rare earth metal Inorganic materials 0.000 description 1
• 150000002910 rare earth metals Chemical class 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 108010051412 reteplase Proteins 0.000 description 1
• 229960002917 reteplase Drugs 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 108020001568 subdomains Proteins 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 102000055501 telomere Human genes 0.000 description 1
• 108091035539 telomere Proteins 0.000 description 1
• 210000003411 telomere Anatomy 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 239000012749 thinning agent Substances 0.000 description 1
• IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 201000006134 tongue cancer Diseases 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1